Kidney disease is one of the more consequential, and less publicly discussed, angles of GLP-1 research. Semaglutide's FLOW trial is the clearest evidence to date that these drugs can affect kidney outcomes specifically, not just weight and blood sugar, and it's already reflected in an FDA-approved use, not just an early research signal.
What the FLOW Trial Tested
FLOW was a large, international, randomized, double-blind, placebo-controlled trial that enrolled 3,533 adults with type 2 diabetes and chronic kidney disease, following participants for a median of 3.4 years. Everyone in the trial continued their standard-of-care treatment; the trial compared adding weekly injectable semaglutide against adding placebo, specifically looking at kidney and cardiovascular outcomes rather than weight loss as the primary question.
What It Found
The trial's primary endpoint was a composite of kidney failure, a substantial and sustained drop in kidney function (measured by eGFR), and death from kidney or cardiovascular causes. Semaglutide reduced the risk of that composite endpoint by 24% relative to placebo. Researchers also reported that the average rate of kidney function decline slowed considerably in the semaglutide group, to about 1.16 mL/min/1.73m² per year, and observed an 18% reduction in major cardiovascular events and a 20% reduction in all-cause mortality in the semaglutide group.
How This Changed Semaglutide's FDA-Approved Status
This isn't preliminary or off-label speculation: based on FLOW's results, the FDA approved semaglutide (marketed as Ozempic) in January 2025 specifically to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That makes kidney protection a distinct, FDA-recognized use of semaglutide in this specific population, alongside its existing approvals for type 2 diabetes management and, under the Wegovy brand, for weight management.
Who This Applies To, and Who It Doesn't
The approval and the underlying trial data are specific to adults who have both type 2 diabetes and chronic kidney disease; it is not a general claim that semaglutide protects the kidneys of everyone who takes it, including people taking it solely for weight management without diabetes or kidney disease, or people taking a different GLP-1 or GIP/GLP-1 medication. Whether similar kidney benefits extend to other drugs in this class, including tirzepatide, is a related but separate research question, and shouldn't be assumed from FLOW's semaglutide-specific results without dedicated trials of those other drugs.
What to Discuss With a Doctor
Chronic kidney disease is a serious, often under-diagnosed condition, and treatment decisions depend heavily on an individual's specific kidney function, other medications, and overall health picture. Anyone with type 2 diabetes and known or suspected kidney disease should talk to their physician about whether their current treatment plan reflects this evidence, rather than making changes to their own medication based on this or any other general summary.
The Bottom Line
The FLOW trial is a well-powered, published, randomized controlled trial, not a preliminary or animal study, and it produced a specific, FDA-recognized change to semaglutide's approved use. It's a good example of how a GLP-1 drug's evidence base and regulatory status can expand well beyond its original approval as more trials are completed, and a reminder that these expanded uses are typically narrow and population-specific rather than blanket claims about the drug class as a whole.